Powder: -20°C for 3 years | In solvent: -80°C for 1 year
FIIN2 是一种 FGFR 的不可逆抑制剂,能够抑制 FGFR1 (IC50:3.1 nM),FGFR2 (IC50:4.3 nM),FGFR3 (IC50:27 nM) 和 FGFR4 (IC50:45 nM)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 357 | 现货 | ||
2 mg | ¥ 483 | 现货 | ||
5 mg | ¥ 662 | 现货 | ||
10 mg | ¥ 1,060 | 现货 | ||
25 mg | ¥ 2,120 | 现货 | ||
50 mg | ¥ 3,180 | 现货 | ||
100 mg | ¥ 4,560 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 925 | 现货 |
产品描述 | FIIN-2, an irreversible, pan-FGFR inhibitor, inhibits FGFR1/2/3/4 with IC50 of 3.09 nM, 4.3 nM, 27 nM and 45.3 nM, respectively. |
靶点活性 | FGFR4:45.3 nM, FGFR3:27 nM, FGFR1:3.09 nM, FGFR2:4.3 nM |
体外活性 | In FGFR1-4 Ba/F3 cells, FIIN-2 inhibits cell proliferation with EC50 in the single- to double-digit nanomolar range. FIIN-2 also shows excellent antiproliferative activity in a variety of backgrounds, including cell lines that have gatekeeper mutations in FGFR1 and that are dependent on FGFR4. [1] |
体内活性 | In a zebrafish developmental model, FIIN-2 causes mild or severe phenotypes to the tail morphogenesis by inhibiting FGFR. [1] |
激酶实验 | Biochemical assays: Biochemical assays are performed by a broad-coverage, TR-FRET-based kinase binding assay platform. |
细胞实验 | NCI-H2077, NCI-H1581, H520, Kato III, AN3CA, RT112, A2780, 4T1, and SKOV-3 cells are treated with inhibitors 1 d after being plated at a density of 1,500 cells per well in 96-well plates. The gatekeeper mutation cell lines are generated by ectopically overexpressing FGFR1 V561M in either NCI-H2077 or NCI-H1581 cells via lentiviral transduction. Cell survival is assessed at 96 h following the addition of inhibitor using the Cell-Titer-Glo reagent according to the manufacturer's instructions. EC50 values are calculated using GraphPad Prism 5. SKOV-3 cells also are treated in the presence of FGF or EGF ligand. Proliferation measurements were made after 96 h using a luminometer. Data are shown as relative values: The luminescence of cells with indicated inhibitor dose is compared with that of untreated cells.(Only for Reference) |
分子量 | 634.73 |
分子式 | C35H38N8O4 |
CAS No. | 1633044-56-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 64 mg/mL (100.8 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.5755 mL | 7.8774 mL | 15.7547 mL | 39.3868 mL |
5 mM | 0.3151 mL | 1.5755 mL | 3.1509 mL | 7.8774 mL | |
10 mM | 0.1575 mL | 0.7877 mL | 1.5755 mL | 3.9387 mL | |
20 mM | 0.0788 mL | 0.3939 mL | 0.7877 mL | 1.9693 mL | |
50 mM | 0.0315 mL | 0.1575 mL | 0.3151 mL | 0.7877 mL | |
100 mM | 0.0158 mL | 0.0788 mL | 0.1575 mL | 0.3939 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
FIIN-2 1633044-56-0 Angiogenesis Tyrosine Kinase/Adaptors FGFR inhibit FIIN 2 Fibroblast growth factor receptor Inhibitor FIIN2 inhibitor